Regulatory response to contaminated valsartan
- PMID: 30209051
- DOI: 10.1136/bmj.k3855
Regulatory response to contaminated valsartan
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following: none.
Comment on
-
Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.BMJ. 2018 Sep 12;362:k3851. doi: 10.1136/bmj.k3851. BMJ. 2018. PMID: 30209057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources